Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

BMEA earnings analysis

Filed May 11, 2026 · Our reading of the company's report

The latest report

Biomea Fusion reported a significant reversal in EPS to $0.27 for Q4 2025 after a series of losses in previous quarters, although revenue remained at $0. Overall, operating expenses were reduced notably to $12.8 million…

Read full summary

Biomea Fusion reported a significant reversal in EPS to $0.27 for Q4 2025 after a series of losses in previous quarters, although revenue remained at $0. Overall, operating expenses were reduced notably to $12.8 million from $29.7 million year-over-year due to decreased R&D and general expenses.

Read the original on SEC.gov

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Mar 2023 May 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

Reported figures

Earnings per share
$0.27

What stood out

  • Strong EPS Recovery

    EPS flipped to $0.27 from a loss of $0.27 in Q3 2025.

  • Operating Expenses Cut

    Operating expenses decreased significantly by approximately $17 million, down to $12.8 million from $29.7 million YoY.

  • R&D Decrease

    R&D expenses were $9.1 million, compared to $22.9 million in the same quarter last year.

  • Cash Position Sustained

    Cash, cash equivalents, and restricted cash stood at $45.1 million as of March 31, 2026.

  • Clinical Trials Progress

    Icovamenib continues to show promise with ongoing clinical trials; FDA lifted hold on its IND applications.

  • Lifecycle Management Improvement

    Efficiency gains from reduced headcount led to better management of R&D expenses.

What to watch

  • No Revenue Generation

    Continues to report $0 in revenue since inception.

  • Significant Accumulated Deficit

    The accumulated deficit amounts to $461.5 million, highlighting ongoing losses.

  • Regulatory and Operational Risks

    Possible delays in regulatory submissions and approvals could hinder product development.

Management's outlook

Management expects to continue incurring significant operational losses.

Earlier filings 4

10-K · March 24, 2026

Biomea Fusion repositioned in 2025 as a clinical‑stage diabetes and obesity company focused on two internal programs: icovamenib (oral menin inhibitor) and BMF‑650 (oral GLP‑1 RA). The company reports promising Phase II…

10-Q · August 5, 2025

Biomea Fusion reported a materially smaller quarterly loss as operating expenses were cut nearly in half: net loss for Q2 2025 was $(20.74)m (−$0.51/share) versus $(37.28)m (−$1.03/share) in Q2 2024. Cash improved…

10-Q · May 5, 2025

Biomea Fusion reported a narrower Q1 2025 net loss of $29,262 (thousands) vs $39,061 (thousands) in Q1 2024 and improved EPS to $(0.80) from $(1.09). Operating expenses declined (total operating expenses $29,712 vs…

10-Q · October 29, 2024

Biomea Fusion (BMEA) reported a Q3 net loss of $32.8M (EPS $(0.91)), wider than Q3 2023 loss of $28.4M (EPS $(0.80)) but improved versus the prior quarter (Q2 2024 EPS $(1.03) to $(0.91)). Cash declined materially to…

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.